Biblio

Found 399 results

Author Keyword Title Type [ Year

]

1997

R. F. Ozols and Vermorken, J. B., “Chemotherapy of advanced ovarian cancer: current status and future directions.”, Semin Oncol, vol. 24, no. 1 Suppl 2, pp. S2-1-S2-9, 1997.

B. K, Kaern, J., Simonsen, E., Piccart, M. J., G, H. Boes, Timmers, P., Roy, J. - A., Pecorelli, S., Stuart, G. C. E., James, K., Cassidy, J., and Kaye, S. B., “Is cisplatin-taxol the standard treatment in advanced ovarian cancer.”, Eur.J.Can. , vol. 33, no. 8, 1997.

P. Harper, “ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.”, Semin Oncol, vol. 24, no. 5 Suppl 15, pp. S15-23-S15-25, 1997.

E. Eisenhauer, Bacon, M., W, W., C, M. D., R, C., N, O., and Zee, B., “Long term survivors from a European-Canadian Trial of paclitaxel in platinum-pretreated ovarian cancer. ”, Eur J Can , vol. 33, no. 8, 1997.

E. Eisenhauer, Vermorken, J. B., and van Glabbeke, M., “Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].”, Ann Oncol, vol. 8, no. 10, pp. 963-8, 1997.

1996

J. B. Vermorken and Pecorelli, S., “Clinical trials in patients with epithelial ovarian cancer: past, present and future.”, Eur J Surg Oncol, vol. 22, no. 5, pp. 455-66, 1996.

W. P. McGuire, Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M., “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”, N Engl J Med, vol. 334, pp. 1-6, 1996.

S. B. Kaye, Paul, J., Cassidy, J., Lewis, C. R., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Davis, J. A., Reed, N. Simon, Crawford, S. M., MacLean, A., Parkin, D., Sarkar, T. K., Kennedy, J., Symonds, R. P., and Group, S. Gynaecolog, “Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group”, J Clin Oncol, vol. 14, pp. 2113-9, 1996.

E. Eisenhauer and Vermorken, J. B., “New drugs in gynecologic oncology.”, Curr Opin Oncol, vol. 8, no. 5, pp. 408-14, 1996.

1995

J. B. Vermorken and Hoekman, K., “Chemotherapy for gynecologic malignancies.”, Curr Opin Oncol, vol. 7, no. 5, pp. 457-65, 1995.

M. E. L. van der Burg, van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., and Pecorelli, S., “The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer”, N Engl J Med, vol. 332, pp. 629-34, 1995.

M. Rotman, Pajak, T. F., Choi, K., Clery, M., Marcial, V., Grigsby, P. W., Cooper, J., and John, M., “Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20”, JAMA, vol. 274, pp. 387-93, 1995.

1994

J. B. Vermorken, “Consolidation therapy in patients with advanced ovarian cancer.”, Eur J Gynaecol Oncol, vol. 15, no. 1, pp. 7-13, 1994.

E. Eisenhauer, Huinink, W. W. ten Bok, Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., and Colombo, N., “European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion”, J Clin Oncol, vol. 12, pp. 2654-66, 1994.

E. Eisenhauer, Huinink, W. W. ten Bok, Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, K., and Colombo, N., “European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.”, J Clin Oncol, vol. 12, no. 12, pp. 2654-66, 1994.

E. Eisenhauer, Bacon, M., Atri, M., M, L., R, N., P, P., E, S., A, F., and N, O., “Radiologic review of response in ovarian cancer: Is it useful? Results from a joint European-Canadian trial. ”, Proc Am Soc Clin Oncol , vol. 13, 1994.

1993

D. G. Allen, Baak, J., Belpomme, D., Berek, J. S., Bertelsen, K., Huinink, W. W. ten Bok, van der Burg, M. E. L., Calvert, A. H., Conte, P. F., and Dauplat, J., “Advanced epithelial ovarian cancer: 1993 consensus statements.”, Ann Oncol, vol. 4 Suppl 4, pp. 83-8, 1993.

J. B. Vermorken, Huinink, W. W. ten Bok, Eisenhauer, E., Favalli, G., Belpomme, D., Conte, P. F., and Kaye, S. B., “Advanced ovarian cancer. Carboplatin versus cisplatin.”, Ann Oncol, vol. 4 Suppl 4, pp. 41-8, 1993.

G. J. S. Rustin, van der Burg, M. E. L., and Berek, J. S., “Advanced ovarian cancer. Tumour markers.”, Ann Oncol, vol. 4 Suppl 4, pp. 71-7, 1993.

“Advanced ovarian cancer: where do we stand and where do we go? Workshop proceedings. June 15-19, 1993, Elsinore, Denmark.”, Ann Oncol, vol. 4 Suppl 4, pp. 1-88, 1993.

M. E. L. van der Burg, Myles, J., Hoskins, P., W, T. Bokkel- Hui, and Eisenhauer, E., “CA-125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancer. ”, Eur.J.Can. , vol. 29A, no. Suppl.6, 1993.

J. T. Thigpen, Bertelsen, K., Eisenhauer, E., Hacker, N. F., Lund, B., and Sessa, C., “Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy.”, Ann Oncol, vol. 4 Suppl 4, pp. 35-40, 1993.

J. B. Vermorken, “The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review.”, Int J Gynecol Cancer, vol. 3, no. 3, pp. 129-142, 1993.

0

K. GB, Vergote, I. B., Stuart, G. C. E., JM, delCampo, Kaern, J., M, B., Lopez, A. B., Hirte, H., E, A. - L., E, L., and O, C., “First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study. Results on overall survival. ”, Eur Soc Gyn Oncol.

Pages